Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Xoma Royalty Corporation (NQ: XOMA ) 27.38 +0.24 (+0.88%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 36,559 Open 27.65 Bid (Size) 10.92 (2) Ask (Size) 28.24 (1) Prev. Close 27.14 Today's Range 26.58 - 27.78 52wk Range 13.48 - 30.36 Shares Outstanding 11,704,467 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC) September 23, 2024 From XOMA Corporation Via GlobeNewswire XOMA Royalty Declares Quarterly Preferred Stock Dividends September 23, 2024 From XOMA Corporation Via GlobeNewswire Performance YTD +31.07% +31.07% 1 Month -5.72% -5.72% 3 Month +5.71% +5.71% 6 Month +6.00% +6.00% 1 Year +98.12% +98.12% More News Read More XOMA Royalty to Present at Upcoming Investor Conferences in September September 04, 2024 From XOMA Corporation Via GlobeNewswire Demystifying XOMA: Insights From 5 Analyst Reviews July 09, 2024 Via Benzinga Peeling Back The Layers: Exploring XOMA Through Analyst Insights May 31, 2024 Via Benzinga Cracking The Code: Understanding Analyst Reviews For XOMA April 29, 2024 Via Benzinga Recap: XOMA Q4 Earnings March 08, 2024 Via Benzinga XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q2 2024 August 13, 2024 Via InvestorPlace XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities August 13, 2024 From XOMA Corporation Via GlobeNewswire FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base July 09, 2024 Via Benzinga Exposures Product Safety XOMA Declares Quarterly Preferred Stock Dividends June 20, 2024 From XOMA Corporation Via GlobeNewswire XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher June 12, 2024 From XOMA Corporation Via GlobeNewswire 3 Crazy Good Stocks to Buy With $500 Right Now June 12, 2024 Via InvestorPlace XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ May 14, 2024 From XOMA Corporation Via GlobeNewswire XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q1 2024 May 09, 2024 Via InvestorPlace XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities May 09, 2024 From XOMA Corporation Via GlobeNewswire XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2% April 30, 2024 From XOMA Corporation Via GlobeNewswire XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) April 25, 2024 From XOMA Corporation Via GlobeNewswire XOMA Corporation Announces Closing of Tender Offer April 03, 2024 From XOMA Corporation Via GlobeNewswire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Kinnate Biopharma Inc. (Nasdaq – KNTE) March 25, 2024 From Brodsky & Smith LLC Via GlobeNewswire XOMA Declares Quarterly Preferred Stock Dividends March 21, 2024 From XOMA Corporation Via GlobeNewswire XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc. March 19, 2024 From XOMA Corporation Via GlobeNewswire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq – March 19, 2024 From Brodsky & Smith LLC Via GlobeNewswire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq – SCTL), California BanCorp (Nasdaq – CALB) March 13, 2024 From Brodsky & Smith LLC Via GlobeNewswire XOMA Stock Earnings: XOMA Misses EPS, Misses Revenue for Q4 2023 March 08, 2024 Via InvestorPlace Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
